Gabather AB (publ) (GABA.ST)
Stockholm · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 0.0198 (-2.94%) as of
Key statistics
- Market cap
- 12.09M
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0182 – 0.1000
- Beta
- -0.71
- Profit margin
- 0.00%
- Volume
- 467.27k
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Södertälje, Sweden
- Employees
- 2
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.